Zeena Salman

Zeena Salman

Auto-generated profile, based on publicly available information

Zeena Salman

Revolution Medicines, Inc., Redwood City, California

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2024 in Cancer Discovery
Verified
Journal Article
Open access
PDF file
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
RAS-driven cancers comprise up to 30% of human cancers. RMC-6236 is a RAS(ON) multi-selective noncovalent inhibitor of the active, GTP-bound state of both mutant and wild-type variants of canonical RAS isoforms with broad therapeutic potential for the aforementioned unmet medical need. RMC-6236 exhibited potent anticancer activity across RAS-addicted cell lines, particularly those harboring mutations at codon 12 of KRAS. Notably, oral administration of RMC-6236 was tolerated in vivo and drove profound tumor regressions across multiple tumor types in a mouse clinical trial with KRASG12X xenograft models. Translational PK/efficacy and PK/PD modeling predicted that daily doses of 100 mg and 300 mg would achieve tumor control and objective responses, respectively, in patients with RAS-driven tumors. Consistent with this, we describe here objective responses in two patients (at 300 mg daily) with advanced KRASG12X lung and pancreatic adenocarcinoma, respectively, demonstrating the initial activity of RMC-6236 in an ongoing phase I/Ib clinical trial (NCT05379985). Significance: The discovery of RMC-6236 enables the first-ever therapeutic evaluation of targeted and concurrent inhibition of canonical mutant and wild-type RAS-GTP in RAS-driven cancers. We demonstrate that broad-spectrum RAS-GTP inhibition is tolerable at exposures that induce profound tumor regressions in preclinical models of, and in patients with, such tumors.

1 February 2024 in Asian Pacific Journal of Cancer Prevention
Verified
Journal Article
Open access
PDF file
YSYaseen Sultan`
Yaseen Sultan`
ZSZeena Salman
Zeena Salman
MAMohammad Alzaatreh
Mohammad Alzaatreh
AEAdib Edilbi
Adib Edilbi
RARuba Al-Ani
Ruba Al-Ani
IQIbrahim Qaddoumi
Ibrahim Qaddoumi
Background: Smoking remains a significant risk factor for numerous health issues, including lung cancer, chronic obstructive pulmonary disease, ischemic heart disease, stroke, and respiratory infections. This study investigates the burden of tobacco-related diseases in the Middle East and North Africa (MENA) region. Methods: Utilizing the GBD data, we examined the risk of smoking and second-hand smoke exposure and their related causes of death and disability in the 22 MENA countries. Smoking prevalence and disease burden data were analyzed with estimates reported as age-standardized rates. Results: Tobacco abuse accounted for 14.5% of all deaths and 23.2% of deaths tied to known risk factors, with an age-standardized death rate of 110.8 per 100,000. Cardiovascular diseases were the primary cause of smoking-related deaths and DALYs, representing 53.4% of all deaths and 50.3% of all DALYs. This was followed by neoplasms (24.6% of all deaths and 20.3% of all DALYs), chronic respiratory diseases(12.4% of all deaths and 11.9% of all DALYs), and respiratory infections and tuberculosis(4% of all deaths and 3.4% of all DALYs). Second-hand smoking caused 20.5% of tobacco-related deaths and 21.5% of tobacco-related DALYs, disproportionately affecting younger individuals. An increasing disease burden was observed in Lebanon, Turkey, Syria, Tunisia, UAE, and Libya, and declining rates were most evident in Oman and Qatar. Conclusion: Our study emphasizes the impact of smoking on cardiovascular disease, the primary cause of smoking-related mortality and morbidity in the MENA region. Our findings highlight the urgent need for effective tobacco control policies and interventions.

1 December 2023 in Molecular Cancer Therapeutics
Verified
Journal Article
Open access
ASAlexander I Spira
Alexander I Spira
ASAlexander N Starodub
Alexander N Starodub
KAKathryn C Arbour
Kathryn C Arbour
DSDavid Sommerhalder
David Sommerhalder
BWBrian M Wolpin
Brian M Wolpin
DHDavid S. Hong
David S. Hong
Background: RMC-6236 is an oral RASMULTI(ON) tri-complex inhibitor that is selective for the active, GTP-bound state of both mutant and wild-type variants of the canonical RAS isoforms. RMC-6236 binds to cyclophilin A, which is abundantly expressed in normal tissues and tumors, resulting in a binary complex that potently binds to RAS(ON) to form a tri-complex, blocking downstream signaling. Preclinical studies with RMC-6236 demonstrated deep and sustained regressions across multiple RASMUT tumor types at well tolerated doses, particularly tumors harboring KRAS glycine-12 substitutions (KRASG12X). Methods: Patients with previously treated, advanced KRASG12X mutant solid tumors were enrolled at escalating doses of single agent RMC-6236 administered once daily (QD). Results: As of May 11, 2023, 54 patients received RMC-6236 at dose levels from 10 to 220 mg QD. The majority of patients had pancreatic cancer (26 [48%]), non-small cell lung cancer (13 [24%]), or colorectal cancer (10 [19%]). The most common (≥10% of patients) treatment-related adverse events (TRAEs) were rash and gastrointestinal (GI)-related toxicities that were all Grade 1 or 2 in severity. Most rashes were acneiform (35%) or maculopapular (13%), consistent with known on-target rash presentation from other RAS pathway inhibitors. Rash frequency, but not severity, was dose-dependent. One patient required a dose reduction due to Grade 2 acneiform rash. The most common GI-related toxicities were nausea (32%), diarrhea (19%), and vomiting (15%) that were manageable with standard supportive care. There were two Grade ≥3 TRAEs in patients with pancreatic cancer: Grade 4 large intestine perforation at the site of an invasive tumor that reduced in size on treatment, and Grade 3 pancreatitis reported at the time of disease progression. Thirty-one patients (57%) remain on treatment, and 23 (43%) discontinued, including 17 (31%) due to progressive disease (PD) per RECIST v1.1, 2 (4%) due to clinical progression, and other reasons due to adverse event (Grade 4 large intestine perforation), death (due to PD), investigator’s decision, or patient withdrawal (1 patient each). RMC-6236 exhibited dose-dependent increases in exposure in patients with no apparent accumulation in the blood following repeated daily dosing. At 220 mg QD, exposure to RMC-6236 was within range of the preclinical exposures in mice that demonstrated significant tumor regressions. Preliminary evidence of anti-tumor activity, including partial responses per RECIST v1.1, was observed in patients across several tumor types and dose levels. Molecular responses were observed with reduction in circulating tumor DNA of the KRAS-mutated allele and other somatic mutations consistent with inhibition of mutant RAS by RMC-6236. Conclusions: RMC-6236 is safe and well tolerated at doses that induce anti-tumor activity in patients with tumors harboring KRASG12X mutations and has favorable pharmacokinetics with oral dosing. A recommended phase 2 dose has not yet been determined and dose escalation is ongoing. Citation Format: Alexander I Spira, Alexander N Starodub, Kathryn C Arbour, David Sommerhalder, Brian M Wolpin, Minal Barve, Ignacio Garrido-Laguna, Salman Punekar, Meredith Pelster, Sumit Kar, Jamie Wong, Tong Lin, Rakesh Raman, Lin Tao, Zeena Salman, Xiaolin Wang, W. Clay Gustafson, David S Hong. Preliminary safety and pharmacokinetic profiles of RMC-6236, a first-in-class, RAS-selective, tri-complex RASMULTI(ON) inhibitor in patients with KRAS mutant solid tumors on the Phase 1 trial RMC-6236-001 [abstract]. In: Proceedings of the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics; 2023 Oct 11-15; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2023;22(12 Suppl):Abstract nr PR010.

1 April 2017 in Journal of Global Oncology
Verified
Journal Article
Open access
DMDavid Mills
David Mills
SASalah Abushanab
Salah Abushanab
AEAwad Elhaloul
Awad Elhaloul
HNHeiam El Nuweiry
Heiam El Nuweiry
MSMohamad Abu Shaaban
Mohamad Abu Shaaban
ZSZeena Salman
Zeena Salman
56 Background: Although cure rates for childhood acute lymphoblastic leukemia (ALL) in developed countries surpass 90%, 1 rates in resource-limited countries, to which barriers to care contribute, are as low as 35%. 2 In the Gaza Strip—a lower middle-income economy 3 —children face unique barriers to ALL treatment. We undertook this work to describe barriers to care for patients with pediatric ALL as well as treatment outcomes at the only pediatric oncology ward in the Gaza Strip. Methods: A comprehensive review of 131 charts was performed. Eighty-four patients met an inclusion criterion of diagnosis of ALL by bone marrow evaluation between 2010 and 2015 in children age < 12 years. Results: Eighty-four patients with ALL (T cell, 12 [14%]; pre-B cell, 72 [86%]) were stratified as being at standard (n = 64; 76%), intermediate (n = 3; 4%), or high risk (HR; n = 17; 20%). Of patients, 100% were referred to an international hospital for definitive diagnosis and induction therapy; 52% required at least one additional international hospital referral as a result of chemotherapy shortages (n = 8), methotrexate monitoring (n = 28), induction failure (n = 5), or relapse (n = 5). Three-year overall survival was 93% (CI, 82% to 97%), event free survival (EFS) was 80% (CI, 66% to 89%; events: death, induction failure, and relapse), and EFS of HR patients was 23% (CI, 4% to 51%). Conclusion: HR patients had extremely poor outcomes, even compared with those in other resource-limited settings. 4 Overall, patients experienced relatively high overall survival and EFS, which was likely confounded by exclusion of HR patients age > 12 years because of low pediatric age cutoff and missing charts. Barriers to care, including limited freedom of movement, contribute to delays in treatment, perhaps affecting outcomes of the HR cohort. An NGL–Ministry of Health partnership is addressing these barriers 5 by providing resources to decrease referrals. AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST: No COIs from the authors.

4 June 2024
Verified
Other
Open access
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
Supplementary Table S1 shows information on the PRISM cell set comprised of 845 cell lines representing more than 45 lineages.

4 June 2024
Verified
Other
Open access
JJJingjing Jiang
Jingjing Jiang
LJLingyan Jiang
Lingyan Jiang
BMBenjamin J. Maldonato
Benjamin J. Maldonato
YWYingyun Wang
Yingyun Wang
MHMatthew Holderfield
Matthew Holderfield
MSMallika Singh
Mallika Singh
Supplementary Table S8 shows all parameter estimates for PK/Efficacy and PK/PD modeling.